ALKS
Alkermes plc.Company Information
- Company Name
- Alkermes plc.
- CIK
- CIK0001520262
- Category
- Large accelerated filer
- Ticker: Exchange
- ALKS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ALKS
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-03
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 265,341
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 170,281,515
- Shares outstanding
- 167,026,000
- Ownership
- 101.95%
Earnings Market Reaction
- Filing date
- 2026-07-28
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 512 | 352 | 389 | 616 | 521 | 400 | 291 | 396 | 535 | 421 | 457 | 648 | ||||||
| Restricted Cash Current | 0 | 0 | 731 | - | - | - | - | - | - | - | - | - | ||||||
| Available For Sale Securities Debt Securities Current | 145 | 160 | 200 | 495 | 495 | 484 | 461 | 513 | 341 | 324 | 316 | 241 | ||||||
| Receivables Net Current | 456 | 408 | 334 | 354 | 355 | 319 | 385 | 367 | 366 | 316 | 332 | 338 | ||||||
| Inventory Net | 299 | 337 | 197 | 191 | 192 | 183 | 183 | 191 | 195 | 198 | 186 | 192 | ||||||
| Prepaid Expense And Other Assets Current | 111 | 102 | 79 | 84 | 71 | 90 | 91 | 94 | 101 | 112 | 98 | 43 | ||||||
| Assets Held For Sale Not Part Of Disposal Group Current | - | - | - | - | - | - | - | - | - | 97 | 94 | - | ||||||
| Contract With Customer Asset Net Current | - | - | 0 | 1 | 1 | 3 | 5 | 3 | 3 | 1 | 1 | 3 | ||||||
| Assets Current | 1,523 | 1,359 | 1,929 | 1,742 | 1,635 | 1,479 | 1,415 | 1,564 | 1,542 | 1,469 | 1,486 | 1,465 | ||||||
| Property Plant And Equipment Net | 218 | 221 | 222 | 247 | 239 | 234 | 228 | 225 | 223 | 225 | 227 | 328 | ||||||
| Long Term Investments | 35 | 26 | 0 | 28 | 38 | 32 | 73 | 19 | 86 | 63 | 40 | 106 | ||||||
| Operating Lease Right Of Use Asset | 76 | 78 | 77 | 79 | 81 | 82 | 84 | 86 | 88 | 90 | 91 | 103 | ||||||
| Intangible Assets Net Including Goodwill | - | - | 84 | 84 | 84 | 84 | 84 | 84 | 84 | - | 85 | - | ||||||
| Intangible Assets Net Excluding Goodwill | 1,761 | 1,784 | - | - | - | - | - | - | - | - | - | - | ||||||
| Goodwill | 594 | 596 | - | - | - | - | - | - | - | 83 | 83 | 93 | ||||||
| Finite Lived Intangible Assets Net | - | - | - | - | - | - | - | - | - | 1 | 2 | 11 | ||||||
| Deferred Income Tax Assets Net | 123 | 135 | 126 | 130 | 156 | 152 | 155 | 160 | 167 | 183 | 196 | 162 | ||||||
| Other Assets Noncurrent | 62 | 59 | 49 | 20 | 20 | 18 | 17 | 17 | 16 | 12 | 12 | 11 | ||||||
| Assets | 4,393 | 4,258 | 2,487 | 2,330 | 2,253 | 2,082 | 2,056 | 2,155 | 2,207 | 2,124 | 2,136 | 2,279 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 332 | 293 | 290 | 215 | 246 | 186 | 185 | 160 | 240 | 206 | 241 | 243 | ||||||
| Operating Lease Liability Current | 7 | 8 | 7 | 7 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 15 | ||||||
| Contract With Customer Liability Current | - | - | 0 | 0 | 1 | 2 | 1 | 2 | 3 | 3 | 3 | 3 | ||||||
| Long Term Debt Current | 27 | 27 | - | - | - | - | - | 3 | 3 | 3 | 3 | 3 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | - | - | - | - | 5 | - | ||||||
| Liabilities Current | 662 | 599 | 543 | 474 | 506 | 444 | 465 | 454 | 516 | 459 | 520 | 503 | ||||||
| Operating Lease Liability Noncurrent | 62 | 64 | 63 | 65 | 66 | 68 | 69 | 71 | 73 | 74 | 76 | 79 | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | 136 | 109 | - | - | - | - | - | - | - | - | - | - | ||||||
| Long Term Debt Noncurrent | 1,477 | 1,484 | - | - | - | - | - | 286 | 286 | 287 | 288 | 288 | ||||||
| Deferred Income Tax Liabilities Net | 180 | 182 | - | - | - | - | - | - | - | - | - | - | ||||||
| Other Liabilities Noncurrent | 68 | 68 | 61 | 57 | 56 | 59 | 56 | 53 | 48 | 49 | 50 | 54 | ||||||
| Liabilities | 2,585 | 2,507 | 668 | 596 | 628 | 570 | 591 | 863 | 923 | 869 | 934 | 924 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Treasury Stock Common Value | -503 | -501 | -450 | -450 | -450 | -448 | -419 | -419 | -303 | -218 | -189 | -187 | ||||||
| Additional Paid In Capital Common Stock | 3,113 | 3,055 | 3,005 | 2,967 | 2,941 | 2,913 | 2,861 | 2,832 | 2,804 | 2,781 | 2,737 | 3,003 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -3 | -3 | -2 | -1 | -1 | -1 | -2 | 0 | -4 | -4 | -3 | -6 | ||||||
| Retained Earnings Accumulated Deficit | -801 | -801 | -735 | -784 | -867 | -954 | -976 | -1,123 | -1,215 | -1,307 | -1,344 | -1,456 | ||||||
| Stockholders Equity | 1,809 | 1,752 | 1,819 | 1,733 | 1,625 | 1,512 | 1,465 | 1,292 | 1,284 | 1,255 | 1,203 | 1,356 | ||||||
| Liabilities And Stockholders Equity | 4,393 | 4,258 | 2,487 | 2,330 | 2,253 | 2,082 | 2,056 | 2,155 | 2,207 | 2,124 | 2,136 | 2,279 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 450 | 450 | 450 | 450 | 450 | 450 | 450 | 450 | 450 | 450 | 450 | 450 | ||||||
| Common Stock Shares Issued | 185 | 184 | 181 | 180 | 180 | 180 | 177 | 176 | 176 | 176 | 173 | 172 | ||||||
| Shares Outstanding | 168 | 166 | 166 | 165 | 165 | 165 | 162 | 162 | 166 | 169 | 167 | 167 | ||||||
| Treasury Stock Common Shares | 17 | 17 | 15 | 15 | 15 | 15 | 14 | 14 | 10 | 7 | 6 | 6 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAlkermes plc. (ALKS) — SEC Financial Statements & Analysis
Alkermes plc. (ALKS) is a pharmaceutical preparations company. Alkermes plc. trades on Nasdaq as: ALKS. Alkermes plc. (ALKS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-28. Based on that filing, Alkermes plc. carries a market cap of $8.75B, a P/E ratio of 132.36x, a P/B ratio of 4.84x, a P/S ratio of 5.25x, an enterprise value of $9.74B, and an EV/EBITDA multiple of 54.47x. On profitability, it posts a gross margin of 84.56%, an operating margin of 7.03%, a net margin of 3.97%, a Return on Equity (ROE) of 3.85%, a Return on Assets (ROA) of 1.99%, and a Return on Invested Capital (ROIC) of 4.02%. Per share, it reports EPS of $0.40, diluted EPS of $0.38, free cash flow per share of $1.33, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 10.79% year-over-year, net income growth of -81.02% year-over-year, and EPS growth of -81.26% year-over-year. On the balance sheet, it maintains a current ratio of 2.30x, a quick ratio of 1.68x, working capital of $860.82M, a debt-to-equity ratio of 1.43x, a debt ratio of 0.59, an interest coverage ratio of 1.98x, free cash flow of $221.61M (TTM), and net debt of $991.58M. Figures sourced from SEC EDGAR.
- Market Cap
- $8.75B
- P/E TTM
- 132.36x
- EPS TTM
- $0.40
- P/B TTM
- 4.84x
- ROE TTM
- 3.85%
- ROA TTM
- 1.99%
- Debt To Equity
- 1.43x
- Free Cash Flow TTM
- $221.61M
- Net Revenue TTM Growth 1Y
- 10.79%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Alkermes plc. in?
Alkermes plc. (ALKS) operates in the Pharmaceutical Preparations industry.
What exchange does ALKS trade on?
Alkermes plc. (ALKS) trades on the Nasdaq.
When was Alkermes plc. (ALKS)'s most recent SEC filing?
Alkermes plc. (ALKS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-28.
What is ALKS's market cap?
Alkermes plc. (ALKS) has a market capitalization of $8.75B as of 2026-06-30.
What is ALKS's P/E ratio?
Alkermes plc. (ALKS)'s trailing twelve month P/E ratio is 132.36x as of 2026-06-30.
What is ALKS's EPS (earnings per share)?
Alkermes plc. (ALKS)'s trailing twelve month EPS is $0.40 as of 2026-06-30.
What is ALKS's ROE (return on equity)?
Alkermes plc. (ALKS)'s trailing twelve month Return on Equity (ROE) is 3.85% as of 2026-06-30.
What is ALKS's ROA (return on assets)?
Alkermes plc. (ALKS)'s trailing twelve month Return on Assets (ROA) is 1.99% as of 2026-06-30.
What is ALKS's ROIC (return on invested capital)?
Alkermes plc. (ALKS)'s trailing twelve month Return on Invested Capital (ROIC) is 4.02% as of 2026-06-30.
What is ALKS's EV/EBITDA?
Alkermes plc. (ALKS)'s trailing twelve month EV/EBITDA is 54.47x as of 2026-06-30.